<DOC>
	<DOC>NCT00544271</DOC>
	<brief_summary>To evaluate the immunogenicity, persistence of antibodies and reactogenicity of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX), when administered to subjects 18-20 months old, compared with not giving a booster DTP vaccine at 18-20 months. Study double blinded for the two DTP vaccines and single blinded for the control arm.</brief_summary>
	<brief_title>Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Male or female children between and including 18 20 months of age at the time of the vaccination. Completed a primary vaccination course with DTPa (INFANRIX) vaccine at 2, 4, and 6 months. Written informed consent obtained before study entry from the parents or guardians of the subject. Free of obvious health problems as established by medical history and clinical examination before entering into the study. Use of any investigational or nonregistered drug or vaccine other than the study vaccine(s) within 30 days preceding the administration of the study vaccine dose, or planned use during the study period. Evidence of previous or intercurrent diphtheria, tetanus, or pertussis disease, or of vaccination against any of these diseases since completion of the primary course of DTPa (INFANRIX) vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>20 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>BOOSTRIX</keyword>
	<keyword>INFANRIX</keyword>
</DOC>